Abstract Treatment with antenatal corticosteroids (ACS) is standard of care for women at risk
of preterm birth between 24 and 34 weeks' gestation. ACS are increasingly used for other …

OBJECTIVE: To describe outcomes for a large cohort of women with prenatally diagnosed
vasa previa, determine the percentage in patients without risk factors, and compare delivery …

Background: Preterm birth, a leading cause of neonatal mortality, has the highest burden in
low-income countries. In 2015, the World Health Organization (WHO) published …

The scientific basis for antenatal corticosteroids (ACS) for women at risk of preterm birth has
rapidly changed in recent years. Two landmark trials—the Antenatal Corticosteroid Trial and …

Preterm birth is the major contributor for neonatal and under-five years mortality rates and
also accounts for a short-and long-term adverse consequences up to adulthood. Perinatal …

Neonatal hypoglycaemia is associated with adverse development, particularly visual-motor
and executive function impairment, in childhood. As neonatal hypoglycaemia is common …

Antenatal Corticosteroids and Magnesium Sulfate for Improved... : Obstetrical & Gynecological
Survey Antenatal Corticosteroids and Magnesium Sulfate for Improved Preterm Neonatal …

Background Antenatal corticosteroids (ACS) are widely prescribed to improve outcomes
following preterm birth. Significant knowledge gaps surround their safety, long-term effects …

Most research on outcomes of preterm birth has centred on babies born at< 32 weeks
gestation and at highest risk of mortality and serious morbidity. Recent years have seen a …

Abstract Background Glucocorticoids (GCs) play a pivotal role in fetal programming.
Antenatal treatment with synthetic GCs (sGCs) in individuals in danger of preterm labor is …